Directors' Share Dealing

RNS Number : 4126O
Hutchison China Meditech Limited
18 August 2017
 

 

 

Directors' Share Dealing

 

London: Friday, August 18, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-

 

(a)      Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited ("WCL"), a person closely associated ("PCA") with Mr To, purchased a total of 4,900 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 15, 2017 at a price of US$24.50 per ADS.  WCL is controlled by the trustee of Wencheng Trust ("WT") which has been established for the benefit of Mr To's family member, of which Mr To is the settlor; and

 

(b)      Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,336 ADSs at an average price of US$24.92 per ADS on August 16 and 17, 2017.

 

Following the above purchases, (i) Mr To is interested in 118,489 ADSs (in Dynamic Drive Trust ("DDT") and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 96,000 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.

 

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

(a)  Wencheng Capital Limited

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Wencheng Capital Limited

 

2

Reason for the notification

 

a)

 

Position/status

 

Person closely associated with Mr Simon To, Executive Director and Chairman.  Wencheng Capital Limited is controlled by the trustee of Wencheng Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor.

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hutchison China MediTech Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

 

ADS each representing one half of one Ordinary Share of US$1.00

 

ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

Acquisition of 4,900 ADSs in the name of Wencheng Capital Limited which holds the ADSs for a family trust (Wencheng Trust) of which Mr To is the settlor on August 15, 2017 at a price of US$24.50 per ADS.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$24.50

4,900

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

N/A

 

 

 

e)

 

Date of the transaction

 

2017-08-15

 

 

f)

 

Place of the transaction

 

Nasdaq Stock Market

 

 

(b) Ms Edith Shih

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Ms Edith Shih

 

2

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director and Company Secretary

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hutchison China MediTech Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

 

ADS each representing one half of one Ordinary Share of US$1.00

 

ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

Acquisition of 5,336 ADSs on August 16 and 17, 2017 at an average price of US$24.92 per ADS.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$24.73

1,000

US$24.74

300

US$24.75

802

US$24.80

400

US$24.79

31

US$25.08

1,748

US$25.07

300

US$25.06

52

US$25.09

703

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

Aggregated volume: 5,336 ADSs

Price information: US$24.92

 

e)

 

Date of the transaction

 

2017-08-16 - acquisition of 2,533 ADSs

2017-08-17 - acquisition of 2,803 ADSs

 

 

f)

 

Place of the transaction

 

Nasdaq Stock Market

 

 

 

About Chi-Med

 

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries

 

 

Mark Lee,

SVP Corporate Finance & Development

+852 2121 8200

 

 

 

 

U.K. & International Media Enquiries

 

Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk

 

 

 

U.S. Based Media Enquiries

 

 

Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

bmiles@bmccommunications.com

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

sduffy@bmccommunications.com

 

 

 

Investor Relations

 

 

Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

mbeck@troutgroup.com

David Dible, Citigate Dewe Rogerson 

+44 7967 566 919 (Mobile)

david.dible@citigatedr.co.uk

 

 

 

Panmure Gordon (UK) Limited

 

 

Richard Gray / Andrew Potts

+44 (20) 7886 2500

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLIFVATAITLID
UK 100

Latest directors dealings